Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Low-Intensity Chemotherapy Combined With Short-Course Blinatumomab on Allo-HSCT in Adults With Newly Diagnosed Ph-B-ALL: A Single-Arm, Prospective, Multicenter, Phase II Study

NCT06930105 is registered in ClinicalTrials.gov with Xianmin Song, MD as lead sponsor.

NCT NCT06930105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06930105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Low-Intensity Chemotherapy Combined With Short-Course Blinatumomab on Allo-HSCT in Adults With Newly Diagnosed Ph-B-ALL: A Single-Arm, Prospective, Multicenter, Phase II Study
Lead sponsor
Xianmin Song, MD
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
May 1, 2028
Enrollment
45 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoid leukemia (all)